Treatment of Isoniazid-Resistant Pulmonary Tuberculosis

Byung-Woo JHUN; Won-Jung KOH.
Tuberculosis and Respiratory Diseases ; : 20-30, 2020.
Artículo en Inglés | WPRIM | ID: wpr-782225

Documentos relacionados

  1. Pharmacokinetics of rifampicin, isoniazid & pyrazinamide during daily & intermittent dosing: A preliminary study.
  2. How Flu-like Syndromes Contribute to Termination of Weekly Rifapentine-Based TB Preventive Therapy Is Still Poorly Predictable.
  3. A Shorter Regimen for Rifampin-Resistant Tuberculosis.
  4. A Shorter Regimen for Rifampin-Resistant Tuberculosis.
  5. A Shorter Regimen for Rifampin-Resistant Tuberculosis. Reply.
  6. A facile one-step jet-milling approach for the preparation of proliposomal dry powder for inhalation as effective delivery system for anti-TB therapeutics.
  7. No evidence of increased risk of acquired rifampin resistance.
  8. Clinical impact of plasma concentrations of first-line antituberculosis drugs.
  9. High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis.
  10. Reply to Decroo <i>et al.</i>: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis.